MRK vs TRVI
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. TRVI: Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated with severe lung diseases like IPF.
Side-by-side fundamentals
| Metric | MRK | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $127.47 | $17.36 | |
| Market cap as of 2026-07-23 | $315.3B | $2.5B | |
| P/E as of 2026-07-23 | 35.29 | n/a | |
| PEG as of 2026-07-23 | 4.34 | n/a | |
| Net margin as of 2026-07-23 | +13.6% | n/a | |
| Gross margin as of 2026-07-23 | +78.1% | n/a | |
| Operating margin as of 2026-07-23 | +18.2% | n/a | |
| ROE as of 2026-07-23 | +17.9% | -24.5% | MRK higher |
| ROA as of 2026-07-23 | +7.0% | -23.4% | MRK higher |
| Debt / equity as of 2026-07-23 | 1.07 | 0.00 | TRVI lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.1% | n/a | |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.21 | 1.02 | |
| 1-year return as of 2026-07-22 close | +56.2% | +166.6% | TRVI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.